Novel Small Molecules to Treat Alzheimer’s Disease

Small compounds that inhibit the uptake of amyloid-β into the brain.


Problem Solved by this Technology

There are over 5 million Americans with Alzheimer's disease (AD). Current therapies target only symptoms and do not inhibit or reverse the cause and progression of the disease. Recent research has identified the transport mechanism of the neurotoxic amyloid-beta (Aβ) protein through the blood-brain barrier as a possible cause of increased Aβ accumulation in sporadic AD. Increased Aβ accumulation occurs in greater than 98% of Alzheimer's patients and is correlated to the disease's symptoms.



Researchers at the University of Rochester have identified compounds that disrupt Aβ transport thus providing the possibility for a new therapeutic approach to AD. These compounds effectively inhibit the interaction between Aβ and its main transport receptor and consequently the uptake of Aβ into the brain.


Unlike current available treatments, these compounds directly target the cause of Alzheimer?s disease rather than treating its symptoms. The target and inhibitory compounds have been validated in vivo.


IP Status

US 8778985 B2 ?Inhibiting amyloid-beta peptide/RAGE interaction at the blood-brain barrier? Issued July 2014.



Deane R. et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. JCI. 2012 Apr 2;122(4):1377-92. PMID:22406537.

URV Reference Number: 6-1473
Patent Information:
Title Country Patent No. Issued Date
Inhibiting Amyloid-Beta Peptide/RAGE Interaction at the Blood-Brain Barrier United States 8,778,985 7/15/2014
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
Berislav Zlokovic
Rashid Deane
Benjamin Miller